Sangamo Therapeutics, Inc.

The transcript did not provide quarterly revenue, EPS, gross margin, or cash figures. The main reported milestones were that the ST-920 rolling BLA submission has begun, with the first 2 modules submitted, and management said they anticipate completing the BLA as early as this summer, subject to adequate additional funding. For guidance, Sangamo said the FDA has reaffirmed accelerated approval for ST-920 based on mean annualized eGFR slope at 52 weeks across all 32 dosed patients, with no confirmatory study required, while 104-week data across those same patients may be used later for traditional approval. Management also said 6 sites are active in ST-503, and ST-506 is still in CTA-enabling activities.

Sandy Macrae framed the quarter as one of continued pipeline execution despite capital-market setbacks. He highlighted progress on the ST-920 BLA, momentum in neurology, and the company’s ASGCT presentations on zinc finger epigenetic regulation and Modular Integrase, saying Sangamo is moving closer to large-scale genome engineering. At the same time, his tone was cautious and pragmatic, repeatedly stressing the need to raise additional capital and maximize asset value through strategic options and business development.

The call did not include a detailed financial review from the interim CFO, and no revenue, EPS, margin, or cash balance figures were disclosed. Instead, management emphasized financing constraints: completion of the ST-920 BLA is expected as early as this summer, but only subject to securing adequate additional funding. They also said they are pursuing multiple ways to raise capital and are being supported by a global investment bank while evaluating strategic alternatives.

Analysts focused on the newly reaffirmed 104-week Fabry endpoint and what it means for timing, data disclosure, and business development. Management said the team is still cleaning the full 2-year dataset and will decide later when and where to submit it, while noting the 1-year data is already in the BLA and that the 2-year data should not delay the accelerated-approval pathway. On BD, management declined to discuss specific talks but said potential partners are likely encouraged by the FDA’s recent affirmation, especially because it removes the need for a second study that would have added cost and delay.